Abstract:AbstractBackgroundApoptotic cell‐conditioned mesenchymal stem cells (AC‐MSCs) exhibit stronger T cell suppressive ability via cyclooxygenase 2 (COX2)/prostaglandin E2 (PGE2); however, whether AC‐MSCs exhibit enhanced therapeutic effects on systemic lupus erythematosus (SLE) remains unknown.MethodsSplenocytes from MRL/MPJ‐Faslpr (MRL/lpr) mice were cocultured with AC‐MSCs, and the proportion of plasma cells was determined by flow cytometry. MSCs, AC‐MSCs, COX2 knockdown MSCs, and COX2 knockdown AC‐MSCs were infused into MRL/lpr mice (n = 10/group). Survival rates and lupus symptoms, including proteinuria, kidney injury, renal immune complex deposition, and autoantibody production, were assessed. Additionally, the number of plasma cells and serum levels of inflammatory cytokines were measured.ResultsThe AC‐MSCs significantly inhibited plasma cells via PGE2 after 24 h coculture in vitro, whereas MSCs did not. In the MRL/lpr mice, AC‐MSC treatment led to a significantly higher survival rate than phosphate‐buffered saline (PBS) treatment (90% vs. 50%, p < 0.05). Moreover, AC‐MSC infusion decreased urine protein levels as early as 1 week after administration (0.89 ± 0.55 mg/mL vs. 1.59 ± 0.60 mg/mL, p < 0.05, compared with PBS treatment). Administration of both MSCs and AC‐MSCs reduced renal immunoglobulin G and complement C3 deposition, whereas COX2 knockdown MSCs and COX2 knockdown AC‐MSCs did not. Serum anti‐dsDNA antibody levels in AC‐MSC‐treated mice significantly decreased (0.40 ± 0.25 vs. 0.99 ± 0.58, p < 0.05), compared with PBS treatment, as well as the number of plasma cells in both the spleen ([2.14 ± 1.05] × 106 vs. [8.02 ± 4.01] × 106, p < 0.01) and renal‐draining lymph nodes ([0.78 ± 0.68] × 106 vs. [2.49 ± 1.45] × 106, p < 0.05). Additionally, AC‐MSCs inhibited the production of inflammatory cytokines, including interleukin‐21, tumor necrosis factor‐alpha, and monocyte chemoattractant protein‐1.ConclusionsAC‐MSCs enhanced the therapeutic effects in mice with lupus, which were partially mediated by COX2/PGE2. Therefore, AC preconditioning may be a new strategy for MSC transplantation in the treatment of SLE.

Apoptosis Of Murine Lupus T Cells Induced By The Selective Cvclooxygenase-2 Inhibitor Celecoxib: Molecular Mechanisms And Therapeutic Potential

Apoptosis of murine lupus T cells induced by the selective cyclooxygenase-2 inhibitor celecoxib: Molecular mechanisms and therapeutic potential

Relationship Between Thinning of Eggshells and Reduction in Number of Eggs Produced after Administration of Some Saluretic Drugs in Domestic Fowls

Protective Effects of Specific Cyclooxygenase-2 Inhibition in the Treatment of MRL/lpr Mice

Mesenchymal Stem Cells Induced CD4+T Cell Apoptosis in Treatment of Lupus Mice

Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.

Effect of Cyclooxygenase-2 Inhibitor on CD4+ CD25+ Regulatory T Cells in Mouse Hepatocellular Carcinoma

Celecoxib induces apoptosis via a mitochondria‑dependent pathway in the H22 mouse hepatoma cell line.

Influence of Specific Cyclooxygenase- 2 Inhibitor on TNF- Α, IL- 6 and Expression CD14 Positive Cells in Lupus MRL/lpr Mice

Cellular FLICE-inhibitory Protein Down-Regulation Contributes to Celecoxib-Induced Apoptosis in Human Lung Cancer Cells.

Protective Effects of Cyclooxygenase‐2 Inhibitors on Narrow‐band Ultraviolet B‐irradiated Epidermal Ia+ Langerhans Cells and Thy‐1+ Dendritic Epidermal T Cells in Mice †

Celecoxib alleviates the DSS-induced ulcerative colitis in mice by enhancing intestinal barrier function, inhibiting ferroptosis and suppressing apoptosis

Enhanced Therapeutic Effects of Apoptotic Cell Conditioned Mesenchymal Stem Cells in Lupus-Prone MRL/lpr Mice

Therapeutic Effects of COX-2 Inhibitor Celecoxib on Nude Mice Bearing Human Pancreatic Cancer Xenograft

Increase of Cyclooxygenase-2 Inhibition with Celecoxib Combined with 5-FU Enhances Tumor Cell Apoptosis and Antitumor Efficacy in a Subcutaneous Implantation Tumor Model of Human Colon Cancer

Overexpression of Cyclooxygenase-2 in Human HepG2, Bel-7402 and SMMC-7721 Hepatoma Cell Lines and Mechanism of Cyclooxygenase-2 Selective Inhibitor Celecoxib-Induced Cell Growth Inhibition and Apoptosis

Celecoxib Exerts a Therapeutic Effect Against Demyelination by Improving the Immune and Inflammatory Microenvironments

[Celecoxib-Induced Apoptosis in Acute Promyelocytic Leukemia Cell Line MR2 and Its Mechanism].

Disruption of Cholangiocyte-B Cell Crosstalk by Blocking the CXCL12-CXCR4 Axis Alleviates Liver Fibrosis.

Celecoxib Induces Cell Apoptosis Coupled with Up-Regulation of the Expression of Vegf by A Mechanism Involving Er Stress in Human Colorectal Cancer Cells

Antiproliferation and apoptosis inducing of cyclooxygenase-2(Cox-2) inhibitor on leukemia HL-60 cells